SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor.

ABSTRACT: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has demonstrated the value of pursuing different vaccine strategies. Vaccines based on whole viruses, a widely used vaccine technology, depend on efficient virus production. This study aimed to establish SARS-CoV-2 production in the scalable packed-bed CelCradle^TM 500-AP bioreactor. CelCradle^TM 500-AP bottles with 0.5 L working volume and 5.5 g BioNOC™ II carriers were seeded with 1.5 × 10⁸ Vero (WHO) cells, approved for vaccine production, in animal component-free medium and infected at a multiplicity of infection of 0.006 at a total cell number of 2.2-2.5 × 10⁹ cells/bottle seven days post cell seeding. Among several tested conditions, two harvests per day and a virus pro

SUBMITTER: Offersgaard A 

PROVIDER: S-EPMC8310283 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature